enGene CEO Pitches Detalimogene as Community-Friendly NMIBC Option, Teases Q2 LEGEND Data Update

enGene (NASDAQ: ENGN) Chief Executive Officer Ron Cooper used a presentation at the Citizens Life Sciences Conference to outline the company's approach to non-muscle invasive bladder cancer (NMIBC), emphasizing both the unmet need in the disease and the company's view that its investigational therapy, detalimogene, could be designed to fit more easily into community urology practices.